Health officials in New South Wales tie a steep jump in emergency department presentations to unapproved peptide products.
Recap by typeshit. Post by @bigbatnews on Instagram.
Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
A short TikTok looks at one peptide product and its claims. The product and the verdict are not named in the listing.
In a JAMA Network Open study of 3,615 adults, GLP-1 use was 20.5% among cancer survivors versus 26.5% in those without cancer, even though survivors carried more heart and kidney risk.
Loading…